PATENT COOPERATION TREATY



PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

<u> </u>						
Applicant's or agent's file reference 29801P WO	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)					
International application No.	International filing d	ate (day/month/year)	Priority date (day/month/year)			
PCT/EP2003/004031	17 April 2003	3 (17.04.2003)	19 April 2002 (19.04.2002)			
International Patent Classification (IPC) or national classification and IPC A23J 7/00						
Applicant						
BIG	GHURT BIOGAI	CDE GmbH & Co.	KG			
 This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36. 						
2. This REPORT consists of a total of	5 sheets	, including this cover s	heet.			
This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).						
These annexes consist of a total of3 sheets.						
3. This report contains indications relating to the following items:						
I Basis of the report						
H Priority						
III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability						
IV Lack of unity of invention						
V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement						
VI Certain documents cited						
VII Certain defects in the international application						
VIII Certain observations on the international application						
			·			
Date of submission of the demand Date of completion of this report						
27 August 2002 (27 08 2002)		•				
27 August 2003 (27.08.2003) 25 August 2004 (25.08.2004)						
Name and mailing address of the IPEA/EP		Authorized officer				
Facsimile No.		Telephone No.				

Translation

International application No.

PCT/EP2003/004031

	OI the re					
1. With	regard to	the elements of the international application:*				
	the inte	mational application as originally filed				
	the des	cription:				
تدع	pages			, as originally filed		
	pages	1-13		, filed with the demand		
	pages		, filed with the letter of	, med with the demand		
K-7	, -		, micd with the letter of			
	the clai	ms:				
	pages			, as originally filed		
	pages		, as amended (together v	with any statement under Article 19		
	pages			, filed with the demand		
	pages	1-14	, filed with the letter of	13 July 2004 (13.07.2004)		
	the drav	vinos.				
	pages	_				
	pages					
	pages			, filed with the demand		
			, filed with the letter of			
	the seque	nce listing part of the description:				
	pages			, as originally filed		
	pages			, filed with the demand		
	pages					
2 117:+1-						
ine ii	iternation	o the language, all the elements marked above were all application was filed, unless otherwise indicated	under this item	Authority in the language in which		
Thes	e elemen	s were available or furnished to this Authority in the		which is:		
	the lang	guage of a translation furnished for the purposes of i	nternational search (under Rule	e 23.1(b)).		
	the lang	guage of publication of the international application	(under Rule 48.3(b)).			
	the lan	guage of the translation furnished for the purposes	of international preliminary e	examination (under Rule 55.2 and/		
	or 55.3).		(
3. With preli	regard minary ex	to any nucleotide and/or amino acid sequence camination was carried out on the basis of the seque	e disclosed in the internation	onal application, the international		
contained in the international application in written form.						
	filed together with the international application in computer readable form. furnished subsequently to this Authority in written form.					
H						
片		ed subsequently to this Authority in computer reada				
	internat	atement that the subsequently furnished written ional application as filed has been furnished.				
	The sta	tement that the information recorded in compute rnished.	r readable form is identical to	the written sequence listing has		
4.	The am	endments have resulted in the cancellation of:				
		he description, pages				
		he claims, Nos.				
		he drawings, sheets/fig				
				ł		
5	beyond	ort has been established as if (some of) the amenda the disclosure as filed, as indicated in the Supplement	nents had not been made, sinc ntal Box (Rule 70.2(c)).**	e they have been considered to go		
in in	icement s is report (0.17).	heets which have been furnished to the receiving O as "originally filed" and are not annexed to ti	ffice in response to an invitation in the first things in the second in	on under Article 14 are referred to contain amendments (Rule 70.16		
** Any r	eplaceme	nt sheet containing such amendments must be refer	red to under item 1 and annexe	d to this report.		
		·				

International application No. PCT/EP 03/04031

V.	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability;
	citations and explanations supporting such statement

1.	Statement			
	Novelty (N)	Claims	14	YES
		Claims	1-13	NÓ
	Inventive step (IS)	Claims		YES
		Claims	1-14	NO
	Industrial applicability (IA)	Claims	1-14	YES
		Claims		NO

2. Citations and explanations

1. Cited documents:

This report makes reference to the following documents:

D1: WO-A-0162226 D2: EP-A-0185442 D3: WO-A-0184961

2. Novelty (PCT Article 33(2))

The concept of "therapeutic application" relates to the treatment of a particular illness with a specific chemical substance or preparation in a particular human or animal organism that requires such treatment. In the absence of an indication of at least (i) the illness or (ii) the nature of the active substance or preparation, a simple method feature is not enough to define a particular method for the therapeutic application.

The subject matter of claim 1 therefore relates to nothing more than the matrix per se.

D1 (see example 2 on page 19) relates to a granular material with a homogeneous solid matrix containing: a/ ≥

International application No. PCT/EP 03/04031

10% w/w soy protein as a vegetable protein, b/ lecithin and c/ aloe vera as an active substance and d/ microcrystalline cellulose. The subject matter of claims 1 to 13 is therefore not novel (PCT Article 33(2)).

D2 (see example 1 in columns 15 and 16) discloses a matrix in granular form containing: a/ hydrogenated palm oil as a carrier material, b/ monoglyceride, c/ 95% acetone-insoluble lecithin (8.3% w/w), and d/ aspartame. The final matrix has an overall diameter between 160 and 30 U.S. standard mesh (= 90-590 microns). The subject matter of claims 1 to 4, 7, 9 and 10 to 13 is therefore not novel (PCT Article 33(2)).

3. Inventive step (PCT Article 33(3))


Since the subject matter of claims 1 to 13 is not novel, it also does not involve inventive step (PCT Article 33(3)).

D1 is regarded as the prior art closest to the subject matter of claim 14.

D1 (see example 2 on page 19) discloses a granular material with a homogeneous solid matrix containing a/ ≥ 10% w/w soy protein as a vegetable protein, b/ lecithin, c/ aloe vera and d/ microcrystalline cellulose.

The subject matter of independent claim 1 differs from D1 in that the phospholipid components are used as bioactive components of a matrix for preventing raised serum cholesterol levels and symptoms of diabetes, and for enhancing mental health, physical endurance and performance.

Claim 14 is therefore novel within the meaning of PCT Article 33(2).



The invention according to claim 1 merely consists in a new application of the granular material known from D1. In this new application, however, only those properties of this granular material are used which are already known from D3 (see page 7, lines 10-24).

The subject matter of claim 14 therefore does not involve inventive step (PCT Article 33(3)).

4. Industrial applicability (PCT Article 33(4))

The subject matter of claims 1 to 14 meets the requirements of PCT Article 33(4) with regard to industrial applicability.